If you have obesity-related conditionssuch as type 2 diabetes, hypertension, or sleep apneastarting now with an approved injectable GLP-1 may make sense
In trial settings, researchers monitor gastrointestinal events closely because they can affect tolerability, participant continuation and interpretation of study outcomes
This rebound effect shows that the drug was working well to manage their obesity, but when they stopped using it, the weight returnedmuch like what would happen to someone with elevated blood pressure or high cholesterol
however, results have been reassuring and consistent with what doctors expect from similar treatments
That means youll pay your plans price, which may be higher than the $50 Bridge copay, meaning the same drug could cost different amounts depending on the reason it is prescribed
This is the question most patients do not think to ask, and it is where the real nuance lives